Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

57.62 +5.54 (+10.63%)
Streaming Delayed Price Updated: 12:32 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
36 37 Next >
News headline image
UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia ↗
The U.K. 
Via Benzinga
News headline image
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket ↗
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. 
Via Benzinga
News headline image
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take. ↗
A few things put together could push the stock higher. 
Via The Motley Fool
News headline image
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Why CRISPR Therapeutics Stock Could Be About to Take Off ↗
CRISPR's financial prospects could soon get an upgrade. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Charged Northward This Week ↗
Gene correction technology took a big step forward this week. 
Via The Motley Fool
News headline image
Invest in the Future With These 7 Forever Stocks ↗
Forever stocks are usually those predicting future trends. Finding them today means pinning down strong financials and prospects without FOMO. 
Via InvestorPlace
News headline image
3 Biotech Stocks With Key Catalysts Coming in December ↗
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner. 
Via InvestorPlace
News headline image
2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher ↗
These stocks look reasonably priced today considering their long-term prospects. 
Via The Motley Fool
Topics Stocks
News headline image
What's Going On With CRISPR Therapeutics Stock? ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target. What To Know: 
Via Benzinga
News headline image
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024 ↗
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year. 
Via InvestorPlace
News headline image
1 No-Brainer Stock to Buy and Hold for 10 Years ↗
This company has been in the news for much of the year. 
Via The Motley Fool
News headline image
3 Growth Stocks to Buy Right Now Without Any Hesitation ↗
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
News headline image
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
News headline image
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues ↗
Vertex shares look cheap today considering all the company has to offer. 
Via The Motley Fool
News headline image
3 Biotech Stocks With the Strongest Clinical Pipelines ↗
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
Via InvestorPlace
News headline image
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. 
Via Investor's Business Daily
News headline image
Why you can make Vertex Pharmaceuticals a buy on any pullback
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely 
Via MarketBeat
News headline image
Why CRISPR Therapeutics Stock Crushed the Market Today ↗
Investors were cheered by the company's latest earnings release, coupled with operational updates. 
Via The Motley Fool
News headline image
Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus ↗
The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments. 
Via Investor's Business Daily
News headline image
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
News headline image
Why CRISPR Therapeutics Stock Is Moving Higher Monday ↗
CRISPR Therapeutics AG (NYSE: CRSP) shares are trading higher Monday after the company announced preclinical data for its investigational programs for the 
Via Benzinga
News headline image
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗
These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors. 
Via The Motley Fool
News headline image
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
News headline image
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗
The meeting went almost as well as could be expected. 
Via The Motley Fool
News headline image
3 Healthcare Stocks to Buy Hand Over Fist in November ↗
Get these stocks while they're cheap. 
Via The Motley Fool
News headline image
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗
This stock could be a long-term winner, thanks to its game-changing technology. 
Via The Motley Fool
News headline image
Why Are Stocks Up Today? ↗
Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates. 
Via InvestorPlace
Topics Economy
News headline image
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? ↗
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. 
Via InvestorPlace
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.